Screener
Immunome IMNM Total Assets
Total Assets at other companies
Other financials
Where this comes from
Reported directly by Immunome in its filing.
Tagged under the XBRL concept us-gaap:Assets.
The source filing: Immunome’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219425
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Operating right-of-use assets | 2,828 | 2,978 |
| Restricted cash | 210 | 210 |
| Other long-term assets | 5,364 | 4,587 |
| Total assets | $619,792 | $683,188 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $5,534 | $3,339 |
| Accrued expenses and other current liabilities | 21,878 | 41,651 |
Item 1. Financial Statements.
FAQ
- What is Immunome's total assets?
- Immunome (IMNM) reported total assets of $619.79M in Q1 2026.
- How has Immunome's total assets changed year-over-year?
- Immunome's total assets increased by 80.9% year-over-year, from $342.69M to $619.79M.
- What is the long-term trend for Immunome's total assets?
- Over 5 years (2020 to 2025), Immunome's total assets has grown at a 72.7% compound annual growth rate (CAGR), from $44.53M to $683.19M.
- What does total assets mean?
- The sum of everything the company owns — current assets, property, investments, goodwill, intangibles, and all other assets.
Ask your AI about Immunome's total assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude